The China size i maximum prices of retail more 400 varietà of drugs in an average of 15 percent, including products Of Pfizer Inc. (PFE), Novartis AG (NOVN) and Merck & Co. (MRK), to reduce the healthcare costs in the nation.
Changes, effective from February 1st, they will concern drugs used for respiratory diseases and for the pain, così come altri drugs specialized he said in a statement about its website the National Development and Reform Commission.
Questa è la fourth series of state mandates for price adjustments as of 2011, with the previous ones cuts for drugs, including antibiotics, vaccines and anti-cancer drugs. The government wants reduce medical expenses for the population Chinese he reported Shanghai Securities News quoting the Minister of Health chen Zhu.
Among the products interested ci sono il Singular per il trattamento dell’asma Of Merck, the Linezolid an antibiotic di Pfizer, il Trileptal un farmaco per l’epilessia by Novartis second a price list issued by government.
The prices of drugs high-end sarà ridotto on average by 20 percent second l’ultimo adeguamento, While some items cheap who offer one limited offer they will have theirs price high to encourage production.
Translation by Riccardo Brevilacqua